Rights & Freedoms · Report · File No. 261117-808
Abortion pill access hangs over Senate panel's Wednesday vote on Trump's FDA pick
A Senate committee votes Nov. 18 on Dr. Heidi Overton, Trump's pick to lead the Food and Drug Administration. The country's best-known anti-abortion group wants senators to hold her up until the administration ends mail-order access to the abortion pill mifepristone. Republicans can lose only one vote.
Every quote in this story (4) was matched word for word against its source. How we work

A Senate committee is set to vote Wednesday, Nov. 18, on Dr. Heidi Overton, President Trump's pick to run the Food and Drug Administration (FDA) 34. The FDA decides how the abortion pill mifepristone can be prescribed. Overton would inherit the agency's safety review of the drug, which is due to finish in March 4.
The country's best-known anti-abortion group now wants Republican senators to hold up her nomination. Its price: the administration must first end mail-order access to the pill 2. Medication abortion made up 63% of U.S. abortions in 2023, according to Guttmacher figures cited by Mother Jones 1.
What the anti-abortion side is demanding
On Nov. 11, SBA Pro-Life America asked senators to get two promises from the Trump administration before moving Overton forward. First, the administration would have to bring back the rule that mifepristone be handed out in person. Second, it would have to change the FDA's ongoing safety study, which the group says has "serious flaws" 2.
Confirmation is not a coronation.
The FDA first approved mifepristone in 2000. Rules adopted under President Biden dropped the in-person requirement, so doctors can prescribe the pill through telehealth, meaning a video or online visit, and send it by mail 1. Mother Jones reports that about 15,000 patients a month get the medication this way, including people in states with near-total bans 1.
From Channel GOPSchumer calls for Hegseth Senate impeachment trialChuck Schumer · 437 plays · captioned, with the source named
A one-vote margin
Overton first needs approval from the Senate Health, Education, Labor and Pensions Committee, known as HELP. Only then can the full Senate vote 4. She needs 11 of the committee's 21 votes 4. Republicans have a one-vote majority on the panel, so a single GOP defection could sink her if every Democrat votes no 3.
The committee chairman, Sen. Bill Cassidy, R-La., wrote on X: "I remain undecided on both of their nominations." He meant Overton and Jim O'Neill, the nominee for National Science Foundation director 3. Cassidy has also called Overton's work on the administration's push to cut back childhood vaccine recommendations "almost disqualifying" 3. Sen. Susan Collins, R-Maine, told NBC News, "I have not taken a position" 4.
Time is running out. Democrats take control of the Senate on Jan. 3. NBC News reports that if Overton is not confirmed by then, her nomination would likely go back to the White House 4. The FDA has had no permanent commissioner since Dr. Marty Makary resigned in May 4.
The nominee's record on the pill
Overton is a physician and a White House domestic policy adviser. She has called the 2022 Dobbs ruling that overturned Roe v. Wade "a huge victory for life" 3. In a 2023 paper for the America First Policy Institute, a conservative think tank, she criticized the FDA's decision to allow mail delivery of mifepristone, calling it "dangerous to women" 4.
At her Sept. 24 confirmation hearing, she was more careful. "Mifepristone was approved by the FDA as having met its safety and efficacy standard," she told Sen. Patty Murray, D-Wash. 5. Asked about the drug's safety rules, she said, "That safety study is ongoing and very important" 5.
Murray was not persuaded. In August she called Overton "a far-right, anti-abortion extremist who has no business leading the FDA" 7.
I am not going to support someone who doesn’t support a woman’s right to make her own choices
Doubts have also come from a Republican. Sen. Lisa Murkowski, R-Alaska, said at the hearing that she believes FDA officials faced "political pressure" to "revisit the approval status of certain products" 5. She warned that requiring in-person dispensing would leave "a very rural state like Alaska" in a "very challenging position," saying about 80% of the state's communities would be affected 5. On Nov. 15, CBS's "Face the Nation" again noted Murkowski's concern about political pressure on the mifepristone review 8.
After the midterms, a harder push
These demands follow a bad election for abortion opponents. In an Election Day memo, SBA president Marjorie Dannenfelser wrote that "Republican turnout was the major problem in this election," according to Mother Jones 1.
Tonight's results are a disaster for the unborn, for their mothers, and for the country as a whole.
Anti-abortion leaders are also again asking the Justice Department to enforce the Comstock Act, a 19th-century federal obscenity law, against abortion pills. Mother Jones says doing that would amount to a national ban 1. Attorney General Todd Blanche reportedly signaled before the election that he was open to it. Mother Jones also cites reporting that White House officials told the Justice Department to hold off on major actions until after the midterms, and told abortion opponents that "the gloves will be off" once the votes were in 1.
That matters because voters keep giving the same answer. Since the Dobbs ruling, voters have decided 22 abortion ballot measures, and abortion-rights positions won 60% of all votes cast on them, Mother Jones reports 1. David Cohen, a legal scholar at Drexel University, warned that any move against the pills would bring "serious blowback" 1.
It's pretty compelling evidence that the American people want abortion rights.
The pattern is clear. After losing at the ballot box, opponents of abortion are trying to get through an unelected agency and a lame-duck Senate what voters have refused them, before a Democratic majority arrives in January 14. Whatever the committee does Wednesday, the Trump administration will still control the FDA review due in March 4.
The Record
- Sen. Patty Murray calls Trump's FDA pick Heidi Overton "a far-right, anti-abortion extremist who has no business leading the FDA" 7.
- At her confirmation hearing, Overton says mifepristone met the FDA's safety and efficacy standard. Sen. Murkowski raises concerns about "political pressure" on the agency 5.
- SBA Pro-Life America urges senators to delay Overton's confirmation until the administration commits to restoring in-person dispensing of mifepristone 2. The HELP committee sets its vote for Nov. 18 3.
- The Senate HELP committee is scheduled to vote on Overton's nomination. Republicans hold a one-vote majority on the panel 3.
Republish this story on your site or in your newsletter
Any site, blog or newsletter may run this story free of charge. Keep the credit line and its link to the original, do not sell it, and edit only for length or house style (the full terms). Photos carry their own licenses, noted under each photo on this page, so use the text alone unless a credit says otherwise.
Paste it into your editor's HTML view. The one-pixel image at the end tells our newsroom the story ran; it stores no reader data.
Sources
- Mother Jones, “Battered by the Midterms, Abortion Foes Turn the Screws on the GOP” (2026-11-16). motherjones.com/politics/2026/11/battered-by-the-midterms-ab
- SBA Pro-Life America (press release), “SBA Urges Senate to Delay Overton Confirmation Until Trump Admin Commits to Abortion Drug Reforms” (2026-11-11). sbaprolife.org/newsroom/press-releases/sba-urges-senate-dela
- The Hill (via Yahoo News), “Senate committee sets key vote for Trump FDA nominee” (2026-11-11). yahoo.com/news/politics/articles/senate-committee-sets-key-v
- NBC News (via Yahoo News), “Trump's FDA pick faces Republican doubts as confirmation deadline nears” (2026-11-12). yahoo.com/news/politics/articles/trump-fda-pick-faces-republ
- States Newsroom via Government Executive, “FDA nominee faces bipartisan scrutiny over vaccines and abortion drug” (2026-09-25). govexec.com/management/2026/09/fda-nominee-faces-bipartisan-
- The New Republic, “The FDA's Overton Window Problem” (2026-09-25). newrepublic.com/post/215869/fda-overton-mifepristone-vaccine
- Common Dreams, “Critics Slam Trump FDA Pick Heidi Overton as 'Anti-Reproductive Rights, Anti-Vax, Anti-Science'” (2026-08-19). commondreams.org/news/trump-nominates-overton
- CBS News, “Full transcript of "Face the Nation with Margaret Brennan," Nov. 15, 2026” (2026-11-15). cbsnews.com/news/face-the-nation-full-transcript-11-15-2026
Found an error? Tell the newsroom. Corrections are noted at the top of the story.
More from the files
Senate health panel sets Nov. 18 vote on Trump's FDA nominee Heidi Overton
The committee will vote on Dr. Heidi Overton a week from today, and its chairman, Sen. Bill Cassidy, says he is undecided. The Food and Drug Administration (FDA) has had no confirmed leader since its last commissioner resigned in May.
Cassidy won't say how he'll vote on Trump's FDA pick ahead of Nov. 18 committee vote
Sen. Bill Cassidy, the Republican who chairs the Senate health committee, says he still has questions about Dr. Heidi Overton. Her nomination could fail if one Republican on the panel votes no.
Abortion-rights group gives new Democratic majorities a to-do list, but Trump's veto looms
Reproductive Freedom for All says the Nov. 3 results were a mandate. Its Nov. 13 memo asks Congress and six newly Democratic states to protect abortion and contraception, and to undo health cuts that older adults feel too. In Washington, a presidential veto still stands in the way.
Delivered free to your door*
The Morning Edition
One short email at 7 a.m. Eastern: the day's top files, one clip worth your time, and the race to watch. Plain English, large type, no clutter.
*Your inbox. Free. Unsubscribe with one click, any time.





